Key Highlights
- According to the Wall Street Journal, Eli Lilly is closing in on a deal to purchase Kelonia Therapeutics for more than $2 billion
- An announcement could come as soon as Monday, with the agreement potentially including milestone-driven payments
- Kelonia specializes in next-generation CAR-T therapy targeting multiple myeloma, a type of blood cancer
- The Boston biotech firm has secured nearly $60 million in funding and carried a valuation slightly above $100 million in 2022
- This acquisition would strengthen Lilly’s cancer treatment portfolio while diversifying beyond its obesity medication leadership
Eli Lilly is reportedly close to finalizing an acquisition of Kelonia Therapeutics, a Boston-based biotech company, for a sum exceeding $2 billion, the Wall Street Journal disclosed Sunday. While an announcement may come as soon as Monday, sources indicate the negotiations remain fluid and could potentially collapse.
According to individuals with knowledge of the discussions cited by the Journal, the agreement may feature supplementary payments contingent on Kelonia achieving specific clinical and regulatory milestones.
Shares of LLY rose approximately 2.55% following the disclosure.
Kelonia operates as a clinical-stage biotechnology firm specializing in CAR-T cell immunotherapy — an innovative treatment methodology that modifies a patient’s immune cells to identify and eliminate cancerous cells.
The company concentrates primarily on multiple myeloma, a blood cancer affecting plasma cells. Its proprietary methodology seeks to streamline CAR-T therapy by eliminating the requirement for chemotherapy preconditioning and reducing the elaborate cellular engineering processes traditionally required.
This represents a significant advancement in the CAR-T landscape, where treatment complexity and logistics have historically created significant barriers.
Kelonia has secured approximately $60 million in capital since its inception. Its most recent valuation in 2022 stood just north of $100 million — indicating the reported acquisition price represents a substantial premium.
Eli Lilly and Kelonia did not respond to Reuters’ requests for comment outside regular business hours.
Expanding Oncology Capabilities
Lilly maintains an established presence in cancer therapeutics. Its current oncology portfolio features Jaypirca and the breast cancer medication Verzenio, alongside several experimental compounds in development.
Acquiring Kelonia would deepen Lilly’s commitment to hematological malignancies, representing one of oncology’s most rapidly expanding therapeutic categories.
This transaction aligns with recent corporate behavior. Lilly has pursued aggressive business development initiatives, supported by substantial revenue streams from its bestselling obesity medication Zepbound and diabetes treatment Mounjaro.
In February, Lilly announced plans to acquire Orna Therapeutics in a transaction valued at up to $2.4 billion. The Kelonia deal would represent another significant transaction within a compressed timeframe.
Diversification Beyond Weight Management
Lilly has openly communicated its diversification objectives. The pharmaceutical company has been extending its reach into inflammatory bowel conditions, ophthalmic diseases, oncology, and gene-editing platforms through strategic acquisitions and collaborative partnerships.
CAR-T immunotherapies align perfectly with this strategic direction. The technology has demonstrated meaningful clinical success in treating hematologic cancers, with multiple therapies already receiving regulatory approval — though manufacturing sophistication and economic accessibility remain industry-wide obstacles.
Kelonia’s streamlined methodology represents its primary value proposition. Should the company successfully demonstrate efficacy while minimizing operational complexity, that competitive differentiation justifies significant investment.
Lilly has not officially confirmed the transaction. The Wall Street Journal noted negotiations could still dissolve prior to any formal announcement.
LLY stock traded up roughly 2.55% in response to the report.
